In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism

Journal of Neural Transmission - Parkinson's Disease and Dementia Section

Volumn 10, Issue 2-3, 1995, Pages 79-89

  Brannan, T ^a   Prikhojan, A ^a   Martinez Tica J ^a   Yahr, M D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cerebral microdialysis; clorgyline; deprenyl; Dopamine; L DOPA; MAO A; MAO B Parkinson's disease; monoamine oxidase; pargyline; Ro 41 1049

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; CARBIDOPA; CLORGYLINE; DOPAMINE; HOMOVANILLIC ACID; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; N (2 AMINOETHYL) 5 (3 FLUOROPHENYL) 4 THIAZOLECARBOXAMIDE; PARGYLINE; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CLORGYLINE; CORPUS STRIATUM; DOPAMINE; HOMOVANILLIC ACID; LEVODOPA; MALE; MICRODIALYSIS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARGYLINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SELEGILINE;

EID: 0029591972     PISSN: 09363076     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/BF02251224     Document Type: Article

References (36)

1. The functional role of monoamine oxidases A and B in the mammalian central nervous system
2. Possible mechanisms of action of (−)deprenyl and other MAO-B inhibitors in some neurological and psychiatric conditions
3. The potentiation of the antikinetic effect after L-dopa treatment by an inhibitor of MAO-B, deprenyl
4. (−)Deprenyl leads to prolongation of Ldopa efficacy in Parkinson's disease
5. Effect of dietary protein on striatal dopamine formation following L-dopa administration: an in vivo study
6. Changes in body temperature markedly affect striatal dopamine release and metabolism: an in vivo study
7. Effect of a selective MAO-A inhibitor (Ro 41-1049) on striatal L-dopa and dopamine metabolism: an in vivo study
8. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease
9. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum
10. The new generation of monoamine oxidase inhibitors
11. Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study
12. Brain microdialysis in rats: a technique to reveal competition in vivo between endogenous dopamine and moclobemide, a RIMA antidepressant
13. From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class or reversible, selective MAO-A and MAO-B inhibitors
14. Stimulation of dopamine transmission in the dorsal caudate nucleus by pargyline as demonstrated by dopamine and acetylcholine microdialysis and FOS immunochemistry
15. Biochemistry and pharmacology of moclobemide, a prototype RIMA
16. Pharmacokinetics and metabolism of selegiline
17. Some observations upon a new inhibitor of monoamine oxidase in brain tissue
18. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats
19. The possible mechanisms of action of (−)deprenyl in Parkinson's disease
20. Deprenyl (selegiline): the history of its development and pharmacological action
21. Topographic immunocytochemical mapping of monoamine oxidase-A, monoamine oxidase-B and tyrosine hydroxylase in human post mortem brain stem
22. Demonstration of monoamine oxidase-A and-B in the human brainstem by a histochemical technique
23. Inhibition of monoamine oxidase-B by (−)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum
24. Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects
25. Deprenyl is metabolized to methamphetamine and amphetamine in man
26. Neurochemical perspectives to the function of monoamine oxidase
27. The efficacy of reversible monoamine oxidase inhibitors in depressive illness
28. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6237 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain
29. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors
30. Norepinephrine, epinephrine, and the sympathomimetic amines
31. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem
32. Drug therapy of parkinsonism
33. Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)
34. Selegiline in the treatment of Parkinson's disease — long term experience
35. Inhibitors of dopamine inactivating systems as antiparkinson drugs